PTC Therapeutics, Inc. Forecast, price target & analysts
PTC Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
PTC Therapeutics, Inc. Classifications & Recommendation:
PTC Therapeutics, Inc. Price Target
| Target Price | $61.20 |
| Price | $49.84 |
| Potential |
22.79%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target PTC Therapeutics, Inc. 2026 .
The average PTC Therapeutics, Inc. target price is $61.20.
This is
22.79%
register free of charge
$117.60
135.96%
register free of charge
$40.40
18.94%
register free of charge
|
|
| A rating was issued by 22 analysts: 15 Analysts recommend PTC Therapeutics, Inc. to buy, 6 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the PTC Therapeutics, Inc. stock has an average upside potential 2026 of
22.79%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 0.81 | 1.79 |
| 13.97% | 121.50% | |
| EBITDA Margin | -10.11% | 50.06% |
| 10,290.58% | 595.37% | |
| Net Margin | -45.03% | 26.56% |
| 32.60% | 158.98% |
18 Analysts have issued a sales forecast PTC Therapeutics, Inc. 2025 . The average PTC Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an PTC Therapeutics, Inc. EBITDA forecast 2025. The average PTC Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 PTC Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average PTC Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.73 | 5.99 |
| 43.49% | 226.64% | |
| P/E | 8.32 | |
| EV/Sales | 2.42 |
18 Analysts have issued a PTC Therapeutics, Inc. forecast for earnings per share. The average PTC Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
PTC Therapeutics, Inc....
Current PTC Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Truist Securities |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 27 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | May 09 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | May 08 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | May 07 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Truist Securities:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 27 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
May 07 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
